Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Future Immunotherapy Response Monitoring will impact treatment and survival of cancer patients

Reference number
Coordinator RISE Research Institutes of Sweden AB
Funding from Vinnova SEK 3 000 000
Project duration April 2024 - March 2026
Status Ongoing
Venture Swelife - Collaboration project for better health
Call Swelife - Collaborative projects for better health autumn 2023

Purpose and goal

The project will develop a simple method to monitor treatment response in lung cancer patients. Tumor-specific mutations will be quantified in circulating tumor DNA from blood samples instead of relying on current X-ray examinations. The method will be validated on samples from lung cancer patients.

Expected effects and result

The project anticipates several notable outcomes: Cost-effective personalized treatment achieved through measuring circulating DNA in blood samples, Improved treatment monitoring by utilizing patients´ specific tumor mutations to track treatment response, reduced risk of adverse effects by clearer monitoring leading to decreased risks, and economic savings accomplished through effective monitoring of treatment.

Planned approach and implementation

The project structure is organized into 5 work packages where WP1 handles project management and dissemination of results, WP2 manages patient selection and choosing the mutations to measure, WP3 develops personalized monitoring of circulating tumor DNA, WP4 measures tumor burden, and WP5 focuses on business development.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 29 April 2024

Reference number 2023-03880